Perioperative Aspirin Management

General Recommendations

• The American College of Chest Physicians recommends that aspirin should be stopped ≤7 days before elective surgery when bleeding risk is significant, but continued if the thrombotic risk outweighs bleeding concerns 1
• For most elective surgeries, aspirin should be discontinued ≤7 days before surgery rather than the traditional 7-10 days 1, 2
• For patients at high risk of thrombotic events, aspirin should be continued perioperatively if the bleeding risk is manageable 3, 4
• The decision to continue or discontinue aspirin should be based on weighing thrombotic risk against surgical bleeding risk 5

Surgery-Specific Considerations

• For neurosurgery and other closed-space surgeries where even minor bleeding can lead to severe complications, aspirin should be withdrawn 5-7 days preoperatively 3
• For high bleeding risk procedures in patients with coronary stents, consider stopping aspirin only if absolutely necessary, and restart as soon as possible 5
• For patients with coronary stents undergoing non-cardiac surgery, aspirin should generally be continued throughout the perioperative period 4

Special Patient Populations

• For patients with drug-eluting stents (DES), aspirin should be continued perioperatively whenever possible 6, 4
• If thienopyridines (e.g., clopidogrel) must be discontinued before major surgery, aspirin should be continued and the thienopyridine restarted as soon as possible 6, 4
• Elective surgery should be delayed until at least 30 days after bare-metal stent (BMS) placement and 12 months after DES placement 5

Resumption of Aspirin Therapy

• Aspirin should be resumed within 24 hours after surgery when adequate hemostasis has been achieved 2
• For patients at high risk of thrombotic events, aspirin should be restarted as soon as possible, ideally within the first 24 hours postoperatively 5, 2

Risks and Benefits Analysis

• Continuing aspirin may increase the frequency of procedural bleeding (relative risk 1.5) but typically does not increase the severity of bleeding complications or perioperative mortality 4
• For cardiac surgery, perioperative aspirin use may increase blood loss but does not increase mortality and is associated with improved bypass graft patency 4

Common Pitfalls and Caveats

• Many clinicians discontinue aspirin for longer than necessary (10 days) when 7 days or less is typically sufficient 1
• Patients may not report over-the-counter use of NSAIDs with antiplatelet effects, so thorough medication reconciliation is essential 2
• Bleeding risk is significantly increased when multiple antiplatelet or anticoagulant medications are combined 2

Perioperative Aspirin Management in Cardiovascular Disease Patients

Decision Framework Based on Surgery Type and Patient Risk

• The American College of Cardiology recommends that patients already taking aspirin preoperatively should continue it through the perioperative period and be discharged on aspirin for CABG, as continuation is associated with reduced risk of myocardial infarction, improved vein graft patency, and reduced ischemic complications 7, 8
• For patients with coronary stents, aspirin must be continued perioperatively regardless of stent type, with elective surgery delayed 4-6 weeks after bare-metal stent placement and 12 months after drug-eluting stent placement, as premature discontinuation markedly increases risk of catastrophic stent thrombosis, death, and myocardial infarction 9
• The American Heart Association, as published in Circulation, recommends that aspirin continuation is specifically recommended for carotid endarterectomy 10, 11
• For most non-cardiac surgery in high CV risk patients, the American Society of Anesthesiologists notes that patients with established coronary artery disease, prior ischemic stroke, or peripheral arterial disease should continue aspirin, as the ASINC trial showed aspirin reduced major cardiac events by 80% in patients with cardiac risk factors undergoing intermediate- or high-risk non-cardiac surgery 10, 11

Risk-Benefit Analysis

• Discontinuation of antiplatelet therapy increases absolute risk of stroke recurrence or cardiovascular event by approximately 2% within 30 days, according to the Anaesthesia journal 10, 11

Critical Caveats

• The American Society of Anesthesiologists guidelines note that aspirin can be continued on a case-by-case basis, with the decision based on weighing thrombotic risk against surgical bleeding risk, and caution that clopidogrel and aspirin should not be stopped in patients with coronary stents placed within specific timeframes 12
• The Anaesthesia journal recommends that aspirin dosage should not be reduced before surgery in patients on long-term aspirin up to 300 mg/day 10, 11

Perioperative Aspirin Management for Foot Surgery

Preoperative Aspirin Discontinuation

• For patients with cardiovascular disease undergoing elective foot surgery, aspirin should be discontinued 3 days before surgery, unless the patient has a coronary stent, in which case aspirin should be continued throughout the perioperative period, as recommended by the French Working Group on Perioperative Haemostasis and supported by the American College of Chest Physicians 13, 14, 15
• The American College of Chest Physicians supports stopping aspirin ≤7 days before surgery, with the understanding that shorter durations are acceptable 16
• For secondary cardiovascular prevention, stop aspirin 3 days before foot surgery, with resumption within 24 hours after surgery once adequate hemostasis is achieved, as recommended by the American College of Chest Physicians and the French Working Group on Perioperative Haemostasis 13, 14, 15, 16

Aspirin Management for Patients with Coronary Stents

• Continue aspirin throughout the perioperative period for patients with coronary stents, as discontinuing aspirin increases the risk of catastrophic stent thrombosis, death, and myocardial infarction, and is supported by the American College of Chest Physicians 15, 16

Bleeding Risk Considerations

• Foot surgery is generally classified as intermediate bleeding risk, which supports the ability to safely continue aspirin in high-risk cardiovascular patients, particularly those with stents, as noted by the American College of Chest Physicians 13, 14
• Discontinuing antiplatelet therapy increases the absolute risk of stroke recurrence or cardiovascular events by approximately 2% within 30 days, highlighting the need for careful risk-benefit analysis, as recommended by the French Working Group on Perioperative Haemostasis and the American College of Chest Physicians 13, 14

Postoperative Aspirin Resumption

• Resume aspirin within 24 hours after surgery when adequate hemostasis is achieved, as recommended by the American College of Chest Physicians 16
• For patients with drug-eluting stents, resuming dual antiplatelet therapy with a 300 mg loading dose of clopidogrel may be recommended by some experts, although this is not universally agreed upon 16

Peri‑operative Aspirin Management for Secondary Cardiovascular Prevention

General Recommendations

• Continue aspirin for secondary prevention in virtually all elective non‑cardiac surgeries, except procedures with exceptionally high bleeding risk such as intracranial neurosurgery (and possibly transurethral prostatectomy). (ACC/AHA guideline, Class IIa, Level B) 17
• For patients on aspirin solely for primary prevention, discontinue aspirin before surgery. (French Working Group on Peri‑operative Haemostasis) 18

Evidence on Thrombotic vs. Bleeding Risks

• Stopping aspirin raises the absolute 30‑day risk of stroke recurrence or major cardiovascular events by ≈2 %. (French Working Group) 18
• Aspirin increases the frequency of procedural bleeding (relative risk ≈ 1.5) but does not worsen bleeding severity or peri‑operative mortality. (ACC/AHA guideline, 2007) 19

Surgery‑Specific Guidance

Procedures in Which Aspirin Should Be Continued (Strong Recommendation)

• Patients with coronary stents – aspirin should be maintained regardless of stent type or age. (ACC/AHA guideline) [17][18]
• Coronary artery bypass graft (CABG) surgery – continue aspirin intra‑operatively and post‑operatively to improve saphenous‑vein graft patency without increasing mortality. (ACC/AHA guideline 2007; ACC/AHA CABG performance measures 2023) [19][20]
• Vascular surgery (peripheral bypass) – routine aspirin continuation improves graft patency. (ACC/AHA guideline 2007) 19

Procedures in Which Aspirin May Be Stopped (Limited Exceptions)

• Intracranial neurosurgery – stop aspirin 5–7 days before the operation to avoid catastrophic intracranial bleeding. (French Working Group) 18
• Transurethral prostatectomy – discontinuation can be considered because of conflicting bleeding data. (ACC/AHA guideline 2007) 19

Stent‑Related Peri‑operative Considerations

• Bare‑metal stent placed <30 days ago or drug‑eluting stent placed <12 months ago – elective surgery should be delayed if feasible. (ACC/AHA guideline) 17
• If surgery cannot be delayed, aspirin should be continued together with dual antiplatelet therapy during the first 4–6 weeks after stent placement. (ACC/AHA guideline) 17
• When a P2Y12 inhibitor must be held, maintain aspirin and restart the P2Y12 agent as soon as hemostasis is achieved post‑operatively. (ACC/AHA guideline; French Working Group) [17][18]

Practical Management Algorithm (Key Steps)

Strength of Evidence

• ACC/AHA 2014 peri‑operative guideline – Class IIa, Level B: “reasonable to continue aspirin when the risk of cardiac events outweighs bleeding risk.” 17
• French Working Group on Peri‑operative Haemostasis 2018 – strong consensus that aspirin should not be stopped for secondary prevention except in high‑bleeding‑risk surgeries. 18
• ACC/AHA 2007 guideline – supports continuation of aspirin in most surgical contexts, noting no increase in mortality despite higher bleeding frequency. 19
• ACC/AHA CABG performance measures 2023 – reinforce peri‑operative aspirin continuation to improve graft patency. 20

Aspirin Management in Patients with Coronary Stents and Cardiovascular Prevention

Risk of Stent Thrombosis When Aspirin Is Discontinued

• In patients who have received a coronary stent, withholding aspirin can lead to very early stent thrombosis, with a median onset of approximately 7 days after discontinuation. This highlights the catastrophic thrombotic risk associated with even short‑term aspirin interruption. 21

Adequacy of Low‑Dose Aspirin for Cardiovascular Prevention

• Reducing the dose of aspirin in individuals on chronic therapy for secondary cardiovascular prevention is not recommended, because lower doses may fail to provide sufficient antiplatelet effect and could compromise protection against thrombotic events. 21